Metabolic plasticity of tumor cell mitochondria offers a high window of opportunity for efficient anti-cancer therapy, since transformed cells have metabolic needs that differ from their non-transformed counterparts, and molecules such PDH, IDH1/2 or glutaminase inhibitors are already in clinical trials. Here, IDH1 is linked to cancer.